The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: We investigated the outcomes of early-stage hepatocellular carcinoma (HCC) patients who showed a complete response (CR) to initial transarterial chemoembolization (TACE), with a focus on the role of scheduled TACE repetition. Methods: A total of 178 patients with early-stage HCC who were initially treated with TACE and showed a CR based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria on one month follow-up computed tomography (CT) were analyzed. Among them, 90 patients underwent scheduled repetition of TACE in the absence of viable tumor on CT. Results: During a median follow-up period of 4.6 years (range: 0.4-8.8 years), mortality was observed in 71 patients (39.9%). The overall recurrence-free and local recurrence-free survival rates at 1 year were 44.4% and 56.2%. In the multivariable model, scheduled repetition of TACE was an independent factor associated with survival (hazard ratio [95% confidence interval]: 0.56 [0.34-0.93], P=0.025). When stratified using Barcelona clinic liver cancer (BCLC) stage, scheduled repetition of TACE was associated with a favorable survival rate in BCLC stage A patients, but not in BCLC 0 patients. Conclusions: Scheduled repetition of TACE was associated with better survival for early-stage HCC patients showing a CR after initial TACE, especially in BCLC stage A patients.
Abstract
Background/Aims: We investigated the outcomes of early-stage hepatocellular carcinoma (HCC) patients who showed a complete response (CR) to initial transarterial chemoembolization (TACE), with a focus on the role of scheduled TACE repetition. Methods: A total of 178 patients with early-stage HCC who were initially treated with TACE and showed a CR based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria on one month follow-up computed tomography (CT) were analyzed. Among them, 90 patients underwent scheduled repetition of TACE in the absence of viable tumor on CT. Results: During a median follow-up period of 4.6 years (range: 0.4-8.8 years), mortality was observed in 71 patients (39.9%). The overall recurrence-free and local recurrence-free survival rates at 1 year were 44.4% and 56.2%. In the multivariable model, scheduled repetition of TACE was an independent factor associated with survival (hazard ratio [95% confidence interval]: 0.56 [0.34-0.93], P=0.025). When stratified using Barcelona clinic liver cancer (BCLC) stage, scheduled repetition of TACE was associated with a favorable survival rate in BCLC stage A patients, but not in BCLC 0 patients. Conclusions: Scheduled repetition of TACE was associated with better survival for early-stage HCC patients showing a CR after initial TACE, especially in BCLC stage A patients.
참고문헌 (17)
- 한국 간 암 스터디그룹, "2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma", Gut and Liver, 9(3), pp.267~317 (2015), 거트앤리버 발행위원회
- Llovet JM, "Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial", Lancet, 359, pp.1734~1739 (2002)
- Lo CM, "Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma", Hepatology, 35, pp.1164~1171 (2002)
- Bruix J, "Management of hepatocellular carcinoma: an update", Hepatology, 53, pp.1020~1022 (2011)
- European Association For The Study Of The Liver, "EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma", J Hepatol, 56, pp.908~943 (2012)
- Park JW, "Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study", Liver Int, 35, pp.2155~2166 (2015)
- Lencioni R, "Modified RECIST (mRECIST) assessment for hepatocellular carcinoma", Semin Liver Dis, 30, pp.52~60 (2010)
- Choi BI, "Therapeutic effect of transcatheter oily chemoembolization therapy for encapsulated nodular hepatocellular carcinoma: CT and pathologic findings", Radiology, 182, pp.709~713 (1992)
- Golfieri R, "Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas", Hepatology, 53, pp.1580~1589 (2011)
- Kim KM, "The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients?", Liver Int, 36, pp.1490~1497 (2016)
- Korean Liver Cancer Study Group, "Practice guidelines for management of hepatocellular carcinoma 2009", Korean J Hepatol, 15, pp.391~423 (2009)
- Yu SJ, "A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016", Clin Mol Hepatol, 22, pp.7~17 (2016)
- 최혜진, "Clinical features of acute viral hepatitis B in Korea: a multi-center study", Clinical and Molecular Hepatology, 17(4), pp.307~312 (2011), 대한간학회
- Kloeckner R, "MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma", Cardiovasc Intervent Radiol, 33, pp.532~540 (2010)
- Lee JK, "Recurrences of hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization", J Gastroenterol Hepatol, 17, pp.52~58 (2002)
- Chung YH, "A strategy for early detection of recurrent hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization", Intervirology, 48, pp.46~51 (2005)
- Kinugasa H, "Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma", J Gastroenterol, 47, pp.421~426 (2012)